SEARCH:   Advanced

Blood, 15 September 2006, Vol. 108, No. 6, pp. 2037-2040. Prepublished online as a Blood First Edition Paper on May 18, 2006; DOI 10.1182/blood-2006-03-009860. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-009860v1 108/6/2037    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kiladjian, J.-J. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Kiladjian, J.-J. Articles by Fenaux, P. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 14, 2006 Accepted May 5, 2006 High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a Jean-Jacques Kiladjian, Bruno Cassinat, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Marie-Laurence Menot, Gerald Massonnet, Jean-Luc Dutel, Kamel Ghomari, Philippe Rousselot, Marie-Jose Grange, Yasmina Chait, William Vainchenker, Nathalie Parquet, Lina Abdelkader-Aljassem, Jean-Francois Bernard, Jean-Didier Rain, Sylvie Chevret, Christine Chomienne, and Pierre Fenaux* AP-HP, Hopital Avicenne AP-HP, Hopital Saint-Louis CHU Dupuytren, Service d'Hematologie CHRU de Lille, Hopital Huriez AP-HP, Hopital Lariboisiere CH de Beauvais CH de Versailles AP-HP, Hopital Bichat CH de Montfermeil INSERM U.790 CH de Chartres Hopital Avicenne/Paris 13 University * Corresponding author; email: pierre.fenaux{at}avc.aphp.fr. V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of peg-IFN-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time PCR. %V617F decreased in 24 of 27 (89%) treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P<0.001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wild type allele was observed during treatment. Those results seem to confirm the hypothesis that IFN preferentially targets the malignant clone in PV, and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Searching for polycythemia vera's Holy Grail Ronald Hoffman Blood 2006 108: 1792-1793. [Full Text] [PDF] This article has been cited by other articles: A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera J. Clin. Oncol., November 10, 2009; 27(32): 5418 - 5424. [Abstract] [Full Text] [PDF] F. Girodon, G. Bonicelli, C. Schaeffer, M. Mounier, S. Carillo, I. Lafon, P. M. Carli, I. Janoray, E. Ferrant, and M. Maynadie Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study Haematologica, June 1, 2009; 94(6): 865 - 869. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] E. Lippert, F. Girodon, E. Hammond, J. Jelinek, N. S. Reading, B. Fehse, K. Hanlon, M. Hermans, C. Richard, S. Swierczek, et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study Haematologica, January 1, 2009; 94(1): 38 - 45. [Abstract] [Full Text] [PDF] A. Theocharides, J. R. Passweg, M. Medinger, R. Looser, S. Li, H. Hao-Shen, A. S. Buser, A. Gratwohl, A. Tichelli, and R. C. Skoda The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders Haematologica, December 1, 2008; 93(12): 1890 - 1893. [Abstract] [Full Text] [PDF] T. S. Larsen, M. B. Moller, K. de Stricker, P. Norgaard, J. Samuelsson, C. Marcher, O. W. Bjerrum, M. T Andersen, and H. C. Hasselbalch Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses. Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 1744 - 1744. [Abstract] F. Girodon, C. Schaeffer, C. Cleyrat, M. Mounier, I. Lafont, F. D. Santos, A. Vidal, M. Maynadie, and S. Hermouet Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy Haematologica, November 1, 2008; 93(11): 1723 - 1727. [Abstract] [Full Text] [PDF] J.-J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, B. Grandchamp, C. Chomienne, and P. Fenaux Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Blood, October 15, 2008; 112(8): 3065 - 3072. [Abstract] [Full Text] [PDF] R. L. Levine and D. G. Gilliland Myeloproliferative disorders Blood, September 15, 2008; 112(6): 2190 - 2198. [Abstract] [Full Text] [PDF] A. Ricksten, L. Palmqvist, P. Johansson, and B. Andreasson Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia Haematologica, August 1, 2008; 93(8): 1260 - 1261. [Full Text] [PDF] J.-J. Kiladjian, F. Cervantes, F. W. G. Leebeek, C. Marzac, B. Cassinat, S. Chevret, D. Cazals-Hatem, A. Plessier, J.-C. Garcia-Pagan, S. D. Murad, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood, May 15, 2008; 111(10): 4922 - 4929. [Abstract] [Full Text] [PDF] E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF] G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation Haematologica, November 1, 2007; 92(11): e118 - e119. [Abstract] [Full Text] [PDF] G. Finazzi and T. Barbui How I treat patients with polycythemia vera Blood, June 15, 2007; 109(12): 5104 - 5111. [Abstract] [Full Text] [PDF] R. A. Mesa Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 355 - 362. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020